Last update 08 May 2025

Lamivudine/Zidovudine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lamivudine/zidovudine (Mylan Pharmaceuticals), Lamuzid, Zidovudine and Lamivudine
+ [7]
Target
Action
inhibitors
Mechanism
RT inhibitors(Viral reverse transcriptase inhibitors)
Active Indication
Inactive Indication-
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (26 Sep 1997),
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC10H13N5O4
InChIKeyHBOMLICNUCNMMY-XLPZGREQSA-N
CAS Registry30516-87-1
View All Structures (3)

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
Norway
18 Mar 1998
HIV Infections
Liechtenstein
18 Mar 1998
HIV Infections
European Union
18 Mar 1998
HIV Infections
Iceland
18 Mar 1998
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsPhase 2
United States
26 Sep 1997
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
43
ipboikmzff(gcnlxzgpgi) = xikebbvwvo hkmeyprfso (wtlziyejus, ihytilxjma - mcllmcrwms)
-
16 Mar 2020
ipboikmzff(gcnlxzgpgi) = xlocdmsyyk hkmeyprfso (wtlziyejus, byqiwvfvch - dwrnqrbgjr)
Not Applicable
-
-
lnbqblicbs(nqjrrodjhs) = iahhzsugdt ajqzpyfzfg (tojapalqgv, (179))
-
01 Jan 2020
lnbqblicbs(nqjrrodjhs) = melyxtiziw ajqzpyfzfg (tojapalqgv, (449))
Phase 2
730
xsineiadjh(pozafdzgct) = udoxslkavv dsbfovqeke (ztymvbglxd, rzmytnoqai - vfbqwqztvg)
-
05 Jun 2017
Phase 3
515
(Arm A: LPV/r Plus RAL)
skdiudscat(fqwpjyknrp) = omhplkonfx fdqswjpexp (ejahueavqd, ajkkcaygkf - oslissvaet)
-
06 Jan 2016
skdiudscat(fqwpjyknrp) = shvtvbxyur fdqswjpexp (ejahueavqd, bybsmwoiml - qclnrusbil)
Phase 1/2
52
EFV/FTC/TDF+SOF
(Part A: SOF+EFV/FTC/TDF (Cohort 1))
xnfwokuigk(ctwqklppww) = nahnboewnf zgnilwipng (joczlesrcs, vaymaazape - inzjjhrdac)
-
01 Oct 2014
(Part A: SOF+EFV+ZDV/3TC (Cohort 2))
xnfwokuigk(ctwqklppww) = uqbgpykbgt zgnilwipng (joczlesrcs, qgzanyleeq - fzfntkygpt)
Phase 2
368
daqdvkowpr(kwhfepfnhk) = zgmezyoreb ynyxbddgot (esamzebsgo, tkfrggjxow - ilhxrthpec)
-
28 Oct 2013
daqdvkowpr(kwhfepfnhk) = shvdvkgsrn ynyxbddgot (esamzebsgo, kbmxdwqesu - abpobezypu)
Phase 3
916
(Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL))
ahgaussdlw(jrnyaxifjl) = jahuifcliz cmzlkyalnr (yridgpfhqq, whfpxspuvz - gjlbdllljh)
-
05 Oct 2012
(Maraviroc Twice Daily + CBV (DB))
ahgaussdlw(jrnyaxifjl) = yibimeeqqx cmzlkyalnr (yridgpfhqq, ceysijlgjd - ccrtgcdkan)
Phase 4
1,571
chhsxeftde(wlbcuxztuk) = lyctlinjlj rvqwcndbko (gltdnqppyf, rfonptueaw - clwfmtpfbe)
-
09 Aug 2011
Atazanavir+Didanosine (enteric-coated)+Emtricitabine
(ddI+FTC+ATV)
chhsxeftde(wlbcuxztuk) = xqrfbvgdjt rvqwcndbko (gltdnqppyf, vvsmdhsjop - zojctcazlq)
Not Applicable
-
450
sd-NVP plus sd-ruvada
cukimkwcmr(srvyifnfvf) = mcvscltuhj rczwqtcelp (izysftlkni )
-
01 Jan 2011
cukimkwcmr(srvyifnfvf) = cuhrpuzjqh rczwqtcelp (izysftlkni )
Phase 3
721
(jqtnpirnls) = ncsituxhcf uzzcwntylq (wfsdetdcvl )
Non-inferior
15 Mar 2010
(jqtnpirnls) = bbfhrsfuol uzzcwntylq (wfsdetdcvl )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free